A Lead Rectangle to Lower the Operator's Radiation Exposure

November 7, 2011 updated by: Sunnybrook Health Sciences Centre

A Lead Rectangle to Lower the Radiation Exposure for Operators Who Uses Radial Approach in Coronary Procedures.

During fluoroscopic imaging, diagnostic information is carried in the primary beam. These high intensity X-rays are the chief hazard to the patient. Lower energy scattered radiation deviates in all directions from the patient. Despite typical precautions (i.e., hanging a lead shield between the patient and the operator), many operators will be exposed to high radiation dose (higher than the permitted 50 miliS per year), this long term radiation exposure may result in stochastic and deterministic effects. The purpose of this study was to test the hypothesis that a non disposable radiation protection drape (that will cover the lower part of the patient) could help minimize the radiation scattered from the patient to the operator. In a procedure done through the Radial approach, there is a large portion of the patients (from the umbilicus and down) that is a source of scatter radiation to the operator. This portion can be covered with a lead rectangle. A non disposable, lead drape of uniform thickness will be inserted into a sterile nylon bag and will be used during fluoroscopic and cineangiography coronary angioplasty procedures. The lead drapes will cover the femoral puncture site. The widths and length of the drape is 50-60cm and 100 cm respectively and was shown not to hinder the field of radiation needed for fluoroscopy and cineangiography. (The upper border of the lead is under the patient's umbilicus and was shown not to interfere with the radiation field needed for angiography or angioplasty).

The Investigators anticipate that the study will show a significant reduction in radiation exposure and hence reduce the radiation hazard to the operator.

Study Overview

Detailed Description

The Investigators tested the hypothesis on a Phantom that contain bones and tissue that simulate human tissue. The above phantom is used in the oncology department for testing radiation protocols delivered to patients. Those preliminary testing showed that a lead rectangle decreased significantly the radiation scattered towards the operators and personnel in the catheterization laboratory. In all chosen places whether 40 or 100 cm from the radiation beam - The Investigators detected a significant reduction in scattered radiation. The significant reduction in these experiments is attributed to the location the Investigators choose but also to the size of the lead drape 100 X60 cm which give a large area of protection. From simple geometric calculations it's understandable that the zone or volume of radiation protection become much larger further away from the lead rectangle.Patients who are admitted for an elective PCI procedure ( or stable ACS patients) will be ask to participate in the study and sign an informed consent. All the procedure will be as standard of care, after cleaning the right or left arm, and the groin a sterile towel will cover the groin, on top of the sterile towel the lead rectangle (that by itself will be inserted to a sterile nylon bag) will be put over to cover the area from the umbilicus and down.

(In case that the radial approach will fail and femoral approach will be needed, it is easy to remove the lead rectangle while keeping sterile field in the groin area). Few dosimeters will be used to assess radiation exposure, two underneath the lead apron, one on top, and two dosimeters for the operator (two detecting the radiation exposure in the neck area).

The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual.

A total of 50 patients will be recruited (based on the Investigators preliminary radiation testing on the phantom and the results of Politi et al). In 25 patients a lead rectangle will be used on top of the regular protection (personal lead suit, leaded glass shield), in 25 patients only regular protection for the operators.

Study Type

Observational

Enrollment (Anticipated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook Health Sciences Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

elective or acute coronary syndrome patients who go through percutaneous coronary intervention at one tertiary centre

Description

Inclusion Criteria:

  • patients referred for an elective (non emergent) - radial access approach for coronary angioplasty.
  • patients with angina pectoris or acute coronary syndrome, which are hemodynamically stable, will be included.
  • Age 18-75.

Exclusion Criteria:

  • Urgent/Emergent procedures (ST elevation myocardial infarction, suspected LM disease, low Ejection fraction <35%, patients in heart failure - NYHA class III, IV).
  • Any situation that there is higher chance (over 10%) of switching to a femoral access approach (like weak radial pulse, low blood pressure <90 mmHg, failed radial access in the past) .
  • Significant valve disease like; severe aortic stenosis, severe mitral regurgitation.
  • Pregnancy or women in child bearing age.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group A - No lead protection
Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group A - no lead protection will be used.
Group B plus lead protection
Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group B - lead protection will be used from the umbilicus and down.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
scattered radiation reduction with lead rectangle protection Vs. no protection at distance of 40-100 cm from the radiation beam
Time Frame: Outcome measure is assessed same day immediately after the procedure (recording the dose of radiation detected by the dosimeters) participants will be followed for the duration of hospital stay, an expected average of 2-4 days.
The Investigators will use "Inlight" (Landauer) dosimeters that are sensitive and can be read over and over to give the differences in scattered radiation, (with or without the lead rectangle). these dosimeters will be read Immediately at the end of the procedure. The investigators will look for the difference in the readings between patients that had the lead rectangle on to patients without the lead rectangle.
Outcome measure is assessed same day immediately after the procedure (recording the dose of radiation detected by the dosimeters) participants will be followed for the duration of hospital stay, an expected average of 2-4 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Bradley H Strauss, MD, PhD, Sunnybrook Health Sciences Centre, Schulich Heart program Devision of Cardiology Toronto Ontario, Canada

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2011

Primary Completion (Anticipated)

July 1, 2012

Study Completion (Anticipated)

July 1, 2012

Study Registration Dates

First Submitted

October 31, 2011

First Submitted That Met QC Criteria

November 7, 2011

First Posted (Estimate)

November 10, 2011

Study Record Updates

Last Update Posted (Estimate)

November 10, 2011

Last Update Submitted That Met QC Criteria

November 7, 2011

Last Verified

November 1, 2011

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Subscribe